• Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ATLN:VX

108.500 CHF 1.500 1.40%

As of 11:43:59 ET on 08/19/2014.

Snapshot for Actelion Ltd (ATLN)

Open: 107.000 Day's Range: 106.500 - 108.600 Volume: 302,191
Previous Close: 107.000 52wk Range: 59.643 - 115.500 1-Yr Rtn: +70.31%

Stock Chart for ATLN

No chart data available.
  • ATLN:VX 108.500
  • 1D
  • 1M
  • 1Y
107.000
Interactive ATLN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ATLN

Current P/E Ratio (ttm) 17.9043
Estimated P/E(12/2014) 20.6000
Relative P/E vs. SMI 0.9043
Earnings Per Share (CHF) (ttm) 6.0600
Est. EPS (CHF) (12/2014) 5.2670
Est. PEG Ratio 1.9095
Market Cap (M CHF) 12,382.93
Shares Outstanding (M) 114.13
30 Day Average Volume 434,232
Price/Book (mrq) 6.6150
Price/Sale (ttm) 6.3641
Dividend Indicated Gross Yield 1.11%
Cash Dividend (CHF) 1.2000
Dividend Ex-Date 05/12/2014
5 Year Dividend Growth -
Next Earnings Announcement 10/21/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ATLN

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)

Company Profile & Key Executives for ATLN

Actelion Ltd. is a pharmaceutical company that develops and markets synthetic small-molecule drugs against diseases related to the endothelium. The Company's drugs, Veletri and Tracleer, are used in the treatment of heart and pulmonary conditions.

Jean-Paul ClozelCEO/Co-FounderAndre C MullerChief Financial Officer
Otto SchwarzExec VP/COOGuy BraunsteinExec VP/Head:Clinical Dev
More Company Profile & Key Executives for ATLN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil